Factor Bioscience to Present Groundbreaking Gene Therapy Research at ASGCT Annual Meeting
Factor Bioscience, a prominent biotechnology company based in Cambridge, MA, is gearing up for a significant presence at the upcoming American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting, scheduled from May 11-15, 2026, in Boston, MA. The company will present seven groundbreaking papers that delve into their latest advancements in gene editing and cell therapy, reflecting over 15 years of pioneering work in the field.
The spotlight will shine on their innovative approaches, including next-generation allogeneic and in vivo CAR-T cell therapies aimed at addressing critical health challenges. Dr. Matt Angel, Co-Founder, Chairman, and CEO of Factor Bioscience, expressed enthusiasm about sharing the most recent data from their pipeline, affirming, "We are excited to report the latest data from our pipeline programs as well as several new innovations at ASGCT 2026." This statement emphasizes their commitment to transformative healthcare solutions that could redefine patient care.
Dr. Kyle Garland, the company’s VP of Research & Development, added, "Over the past year, we have made significant progress developing next-generation therapeutics that have the potential to treat some of the most intractable diseases by overcoming the limitations of conventional therapies." This underscores Factor's dedication to merging scientific innovation with practical therapeutic applications.
Among the seven presentations, attendees can expect to see:
The insights shared at this conference present a golden opportunity for collaboration and discussion among leaders in the field, aiming to bridge the gap between academic research and therapeutic application.
As Factor Bioscience continues to push the boundaries of biotechnology, their work at ASGCT 2026 will undoubtedly contribute to the larger dialogue on the future of gene and cell therapy. For more information on this year's ASGCT Annual Meeting, you can visit ASGCT Annual Meeting or check out Factor's official page for ongoing updates on their research and innovations.
The spotlight will shine on their innovative approaches, including next-generation allogeneic and in vivo CAR-T cell therapies aimed at addressing critical health challenges. Dr. Matt Angel, Co-Founder, Chairman, and CEO of Factor Bioscience, expressed enthusiasm about sharing the most recent data from their pipeline, affirming, "We are excited to report the latest data from our pipeline programs as well as several new innovations at ASGCT 2026." This statement emphasizes their commitment to transformative healthcare solutions that could redefine patient care.
Dr. Kyle Garland, the company’s VP of Research & Development, added, "Over the past year, we have made significant progress developing next-generation therapeutics that have the potential to treat some of the most intractable diseases by overcoming the limitations of conventional therapies." This underscores Factor's dedication to merging scientific innovation with practical therapeutic applications.
Among the seven presentations, attendees can expect to see:
- - In vivo CAR-T Platform: This platform leverages high-fidelity synthetic RNA to enable selective protein expression in CD8+ T cells, promising enhanced effectiveness in targeting cancer cells. The presentation will be delivered by Joseph Pisano on May 12.
- - TCR-Replaced CAR T Cells: Ian Hay will present findings related to TCR-replaced CAR T cells showcasing a mutant CD28 co-stimulatory domain that enhances memory phenotype, potentially leading to more effective cancer treatments during tumor rechallenge assays.
- - IL-12-Engineered Macrophages: Lindsey Sabo will highlight how transplant-ready IL-12-engineered iPSC-derived macrophages exhibit solid tumor-killing activity while maintaining viability post-thaw, crucial for therapeutic applications in high-stakes health situations.
- - iPSC-Derived Mesenchymal Stromal Cells: Christopher B. Rohde will detail how engineered iPSC-derived mesenchymal stromal cells improve muscle function in mdx mouse models of muscular dystrophy, indicating progress in treating muscular disorders.
- - Glioblastoma Multiforme Model: Katherine Klosterman will address how IL12-secreting macrophages can enhance cytotoxic T cell activity against glioblastoma multiforme models, showcasing the importance of counteracting immunosuppressive tumor microenvironments.
- - RNA-Based Reprogramming: Cassandra Ng will discuss a novel RNA-based approach for human fibroblast reprogramming without employing modified nucleotides that could induce strand slippage, paving the way for safer gene therapies.
- - HTRA1-Expressing MSCs: Finally, Taeyun Kim will present findings on engineered iPSC-derived MSCs that reduce Tau fibrils, a significant aspect of neurodegenerative disorder research.
The insights shared at this conference present a golden opportunity for collaboration and discussion among leaders in the field, aiming to bridge the gap between academic research and therapeutic application.
As Factor Bioscience continues to push the boundaries of biotechnology, their work at ASGCT 2026 will undoubtedly contribute to the larger dialogue on the future of gene and cell therapy. For more information on this year's ASGCT Annual Meeting, you can visit ASGCT Annual Meeting or check out Factor's official page for ongoing updates on their research and innovations.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.